Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

OpenAI’s Revenue Run Rate Tops $40 Billion, Roughly Doubling in Eight Months as AI Coding Tools Drive Explosive Growth

by Team Lumida
4 hours ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI's annualized revenue run rate has surpassed $40 billion, roughly double its end-of-2025 figure, fueled by Codex AI coding tools, subscriptions, and nascent advertising — with growth accelerating...

Read more

DeepMind’s Demis Hassabis Pitched an “IAEA for AI” to Lab CEOs and Trump Officials Before Stepping Down — A New Independent Safety Body to Govern the Race to AGI

by Team Lumida
1 day ago
DeepMind’s Demis Hassabis Pitched an “IAEA for AI” to Lab CEOs and Trump Officials Before Stepping Down — A New Independent Safety Body to Govern the Race to AGI

Hassabis held discussions with AI lab leaders and Trump administration officials including Scott Bessent about forming an independent AI safety body modeled on the IAEA — before relinquishing...

Read more

Anthropic in Talks to Acquire Decart AI for $6 Billion — World Models, Chip Efficiency Tech, and a Pre-IPO Bet on Infrastructure Supremacy

by Team Lumida
1 day ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic is in talks to buy Decart AI for ~$6B ahead of its IPO. Decart's chip efficiency software and world models would slot into Anthropic's inference and performance...

Read more

Apple Is Paying Publishers for Real-Time News to Power AI Siri — Multiyear Content Deals Signal a Different Strategy Than the “Scrape First” AI Playbook

by Team Lumida
1 day ago
Why Apple’s AI Approach May Save Its Reputation

Apple has approached publishers with multiyear licensing deals to feed current news into AI Siri, expected to roll out later this year — a proactive contrast to competitors...

Read more

The AI Power Trade Is Stalling — Vistra and Constellation Energy Face Regulatory Headwinds as the Easy Part of the Power Bull Case Gets Complicated

by Team Lumida
2 days ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Vistra and Constellation soared on the AI power demand thesis, but regulatory shifts and data center backlash are clouding the story. Constellation doesn't expect clarity until Q2 2027.

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
2 days ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
3 days ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more

Zuckerberg’s 6,500-Word AI Manifesto: Open AI Access, No ‘Benevolent Superintelligence,’ $1 Billion for Data Center Communities — and a Direct Challenge to OpenAI and Anthropic

by Team Lumida
3 days ago
Metaverse Meets AI: A Game-Changer for Investors

Mark Zuckerberg published a sweeping 6,500-word essay staking out Meta's philosophical position on AI: that concentrated control of AI is inherently dangerous, that open access diffuses power more...

Read more

China Unleashes Its $28 Trillion Capital Markets to Win the AI Race — CXMT IPO Surges 500%, Becomes China’s Most Valuable Stock

by Team Lumida
4 days ago
China’s Bold Economic Moves: What You Need to Know Now

Beijing is pivoting from subsidies to capital markets to fund its AI ambitions, with memory chip maker CXMT's extraordinary Shanghai debut — surging 500% to become China's most...

Read more

Google’s AI Is Killing the Web — Now Cloudflare and UK Regulators Are Fighting Back

by Team Lumida
4 days ago
Alphabet $GOOGL Q2 2024 Results

Google's search crawler secretly feeds both its search index and its Gemini AI model, making it impossible for publishers to block AI scraping without losing search traffic. Cloudflare...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

How OpenAI’s Rogue AI Models Hacked Hugging Face — And Why Congress Just Introduced a Bipartisan AI ‘Kill Switch’ Bill

July 24, 2026
a close up of a clock with different colored numbers

Global Stocks Near Record Highs: What This Means for You

August 22, 2024
The Real AI Threat at Work: Your Know-How Becomes the Company’s Asset

The Real AI Threat at Work: Your Know-How Becomes the Company’s Asset

February 16, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018